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high likelihood of recipients of blood transfusion being given SCT red
cells in these countries.
SCT red cells contain about 40% HbS (in the absence of co-inheri-
tance of other haemoglobinopathies such as α thalassaemias), with
HbA representing the balance. The presence of HbA dilutes HbS and
greatly reduces the probability of polymer formation. HaematologicalSickle cell
Sickle cell trait
Red cellsThe complications of sickle cell disease (SCD) arise from the pres-
ence in red cells of the mutated haemoglobin, HbS, which replaces the
normal adult Hb,HbA. HbS has a single amino acid substitutionwhereby
valine replaces glutamic acid in the 6th codon of the β chain. Most SCD
patients inherit two copies of the sickle gene (homozygous HbSS indi-
viduals - sometimes termed sickle cell anaemia, SCA). About a third of
SCD patients co-inherit HbS with a second abnormal Hb, HbC, in
which lysine replaces glutamic acid in the same codon (heterozygous
HbSC individuals). There are also a number of rarer genotypes of SCD
such as HbS/β thalassaemia.
The initial event in pathogenesis of SCD is the ability of the
neighbouring molecules of HbS to aggregate into long, rigid polymers
following deoxygenation. There are multiple sequelae including altered
red cell rheology, fragility, increased cation permeability and stickiness.
These events result in the two main complications of SCD, a chronic
anaemia and acute episodes of ischaemia, which can elicit pain and
also damage multiple tissues in organs including the brain, lungs,
bones and kidney.
Sickle cell trait (SCT) individuals inherit one copy of HbA and one
of HbS (HbAS). The selection pressure for HbS lies in the relative
protection of these heterozygotes from the severest form of malaria,
Plasmodium falciparum. There are hundreds of millions SCT individuals
worldwide. About 9% blacks (3 million people), 0.2% Caucasians and
1.5% babies in USA have SCT. In the UK, there are about a quarter of a
million individualswith SCT. Prevalence is even higher in areas endemic
formalaria, with SCT reaching around 25% in someparts of Africa and upm.2016.08.006.
ited Kingdom.
. This is an open access article underto 60% in some areas of Saudi Arabia. Without screening, there is thus a
parameters of SCT individuals are largely normal - Hb levels, red cell
size and shape and a lack of intravascular haemolysis. Whilst some
mild abnormalities are present, including reduced red cell
deformability, these are usually considered subclinical (Tripette et al.,
2009). The propensity for HbS polymerisation and red cell sickling is en-
hanced by hypoxia, acidosis and hypertonicity and can be induced in
SCT red cells in vitro although it remains questionable whether poly-
merisation occurs to a signiﬁcant extent in vivo (O'Connor et al., 2012).
On the whole, SCT is generally regarded as a benign condition
(Steinberg, 2001). Notwithstanding, there are reports to the contrary.
“Exercise collapse associated with SCT” (or ECAST) has been described
in the military and elite civilian athletes (Jones et al., 1970; Harmon et
al., 2012). High levels of exertion have been associated with rhabdomy-
olysis and death. Acute problems are usually avoided with good hydra-
tion, oxygenation and avoidance of temperature extremes and it has
been questioned whether SCT is the true precipitating cause
(O'Connor et al., 2012; Steinberg, 2001; Kark and Ward, 1994). The
major clinical importance of SCT lies with genetic counseling and family
planning (e.g. NHS screening programme & Sickle Cell Disease Associa-
tion of America).
Several complications have been increasingly linked to SCT, howev-
er, including splenic infarction at high altitude, venous thromboembo-
lism and renal damage. The latter probably represent the most serious,
with an increased risk of renal medullary cell carcinoma, haematuria
and nephropathy (Goldsmith et al., 2012). Inability to concentrate
urine (hyposthenuria) correlates with amount of HbS polymer in SCT
individuals (Gupta et al., 1991). Medullary hypoxia, acidosis and slug-
gish blood ﬂow all promote HbS polymerisation and contribute to the
particular vulnerability of this organ.
In EBioMedicine, Osei-Hwedieh et al. present data which show that
older stored samples of human SCT red cells have increased fragility
in vitro and also decreased in vivo survival in a mouse model
(Osei-Hwedieh et al., 2016). These results are perhaps not surprising,
but their work emphasises that our appreciation of the condition is in-
complete and highlight the need for further studies including use of
SCT red cells for transfusion, especially in areas of greater prevalence
of the genotype.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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some countries, people with SCT can act as blood donors, but only the
plasma is used, as the red cells cause problems with blocking ﬁlters
used for leucodepletion (Bodensteiner, 1994). Elsewhere, SCT red cells
may be transfused into patients, but would usually be avoided in certain
situations, such as when the recipient has SCD or is a neonate (Novak
and Brown, 1982).
The present paper suggests that more caution should be used when
considering or producing guidelines on blood donation from people
with SCT. The majority of the countries where SCT is very prevalent,
however, are in sub-Saharan Africa where safe blood transfusion is
often not available, and donation from relatives is often the norm. In
these circumstances, it may be difﬁcult to argue that it is better to
avoid transfusions from those with SCT, when the alternative may be
no transfusion at all.
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